428 results about "Intestinal Cancer" patented technology

The invention discloses application of dihydromyricetin in preparing a medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor. In particular, the application is to prepare medicines for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, preventing and treating arrest of bone marrow and baldness, resisting mutation, preventing and treating the generation of secondary tumors, preventing and treating tumor transfer, and preventing and treating breast cancer, cervical carcinoma, intestinal cancer and the like. The invention creatively finds that the dihydromyricetin has the effects of removing free radicals, inhibiting reaction chains of the free radicals, resisting the mutation, inhibiting the expression of the tumor gene, causing the death of tumor cells, preventing and treating the tumor generation, preventing and treating the secondary tumors and the transfer of the secondary tumors and preventing and treating infection. Therefore, as the medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, the dihydromyricetin can inhibit and alleviate chemical damage, prevent and treat damage of a mutagen and further prevent gene mutation or the secondary tumors; and by combination with the radiotherapy and chemotherapy, the effects of preventing untoward reactions in radiotherapy and chemotherapy of tumor and preventing generation of tumors are achieved.

The present invention discloses CRISPR/Cas9 targeted knockout human intestinal cancer cell RITA gene and specific sgRNA thereof. First, sgRNA specifically targeted to a second exon of the RITA gene isobtained, and the base sequence of the sgRNA is as shown in SEQ ID NO. 1; secondly, a sgRNA lentiviral vector system of the RITA gene is constructed, and the sgRNA lentiviral vector system contains Cas9 protein; and finally human intestinal cancer HT-29 cells are infected with CRISPR/Cas9 lentivirus containing the sgRNA to obtain a cell line which is significantly reduced in RITA protein expression level. The invention has the advantages of simple operation steps, good sgRNA targeting property, and high RITA gene cutting efficiency; furthermore, the constructed CRISPR/Cas9 lentivirus system has the advantage of high knock-out efficiency and can specifically knock out the RITA gene to obtain RITA gene-knockout human intestinal cancer cells, and a powerful tool for the further study of theaction mechanism of RITA in the intestinal cancer cells is provided.

An edible-fiber food for decreasing blood fat and cholesterol, regulating blood sugar, moistening intestine, and preventing constipation, cardiovascular and cerebrovascular diseases, diabetes, intestinal cancer and breast cancer is prepared from water-insoluble fibers (19-80 Wt%) and water-soluble fibers (20-79%).

The invention discloses a CRISPR-Cas9 for targeting knockout of a human intestinal cancer cell CNR1 gene, and specific sgRNA sequences thereof. Firstly, an sgRNA specifically targeting CNR1 gene second exon is obtained, and base sequences of the sgRNA are as shown in SEQ ID NO. 1; secondly, the sgRNA of the CNR1 gene is constructed to a lentiviral vector system, and the lentiviral vector system contains Cas9 protein; and finally, a CRISPR/Cas9 lentivirus containing the sgRNA is infected with human intestinal cancer HT-29 cells, and a cell strain with CNR1 protein expression level significantlybeing reduced is obtained. The operation steps are simple, good sgRNA targeting is achieved, and the cutting efficiency to the CNR1 gene is high; and in addition, the constructed CRISPR/Cas9 lentiviral system has the advantage of high knockout efficiency, and can specifically knock out the CNR1 gene, human intestinal cancer cells with the CNR1 gene being knocked out is obtained, and therefore a powerful tool for further study of the mechanism of action of CNR1 in intestinal cancer cells is provided.

A magnetic nanoparticle-human liver cancer resistant monoclonal antibody Hab18 or its fragment Hab18F (abí»)2 or Hab18Fab as the target medicine in the form of injection for preventing and treating the liver cancer, stomach cancer and intestinal cancer by magneto-thermal therapy is proportionally prepared from magnetic nanoparticles and said antibody. Under the action of magnetic field, it can generate the heat 10-7000 W/gFe to kill cancer cells.

The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549 and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.

The invention provides a veratramine degradation product veratrum fluorene aldehyde 1 and derivatives thereof. The invention uses steroidal alkaloid veratramine (A) as raw material and prepares veratrum fluorene aldehyde by oxidative degradation of m-chloroperoxybenzoic acid to obtain 20 derivative compounds of the veratrum fluorene aldehyde 1 after further oxidation, reduction and condensation reaction. The 20 compounds of the invention have good inhibitory activity on cancer cells, wherein the compounds 1, 2, 5, 8, 13 and 17 have good inhibitory activity on cells of human pancreatic cancer cells BxPC-3 and SW1990, small-cell lung cancer cells NCI-H446, human colorectal cancer LOVO and the like, and the inhibitory activity of the compound veratrum fluorene aldehyde 1 is the most significant.

The invention discloses a Chinese medicinal composition for treating malignant tumor, belonging to the field of Chinese medicines. The Chinese medicinal composition is a medicament preparation formed from herba oldenlandiae, astragalus root, tuckahoe, prepared pinellia tuber, herba scutellariae barbatae, teloon, scorpion, scolopendra and the like by adopting advanced processes including extraction with water, extraction with ethanol, enzymolysis of trypsinase and the like according to a certain compatible requirement, and the medicament preparation is preferably prepared into capsules and tablets. The Chinese medicinal composition has a certain function for relieving symptoms for lung cancer, liver cancer, gastric cancer, intestinal cancer, breast cancer, encephaloma, lymph cancer and other malignant tumors, reducing tumor bodies, inhibiting the growth of the tumors and the like; and according to the Chinese medicinal composition, the human immune capability can be improved, the lives of patients suffered from tumors can be prolonged and the adverse reactions of leukocytopenia, dizzy, weakness and fatigue, skinniness, poor appetite, nausea and vomiting and the like due to radiotherapy chemotherapy for cancers can be effectively relieved.

The invention discloses an intestinal flora maker for intestinal cancer and an application of the intestinal flora maker, and belongs to the technical fields of microorganisms and genetic engineering.The intestinal flora maker comprises megasphaera, veillenella, streptococci, bilophila sp., haemophilus, corynebacterium or Escherichia-Shigella. Through detection by the intestinal flora maker, risks of individuals suffering from intestinal cancer can be assessed, and auxiliary reference can be provided for disease diagnosis and prognosis monitoring.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,

and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT₁, 5-HT_1A, 5-HT₂ receptors, 5-HT_2A and 5-HT_2B receptors, dopamine receptors and multiple kinase pathways.

The invention relates to a medicament-tumor number 1 capable of killing cancer cells and curing various tumors and cancers and leukemia. The medicament comprises glossy ganoderma, ginseng, herba epimedii, astragalus membranaceus, giant knotweed rhizome, Chinese caterpillar fungus, heartleaf houttuynia herb and liquorice root. The medicament capable of killing cancer cells and curing various tumors and cancers and leukemia is prepared by pure traditional Chinese medicine, is good in treatment effects, less in side effects, short in treatment course and the like, is rapid in effect and high in cure rate, has effects of killing cancer cells and improving human body immunity, has functions of prolonging life and anti-aging and is capable of curing leukemia and various tumors and cancers, such as leukemia, bone cancer, lymphoma, intestinal cancer, liver cancer, renal carcinoma, gastric cancer, pelvic cancer, uterine cancer, cervical cancer, bladder cancer, prostatic cancer, pancreatic cancer, lung cancer, brain cancer, neuroendocrine tumor, mammary cancer and esophageal cancer.

The invention relates to a preparation method of health care sobering jelly. The preparation method comprises the steps of solid ingredient mixing, colloid dissolution, colloid boiling, proportioning, filling, sealing and sterilization. Konjac glucomannan and arrowroot powder are used as major ingredients and are dissolved with water solution for forming gel. The prepared health care sobering jelly has the advantages that the mouth feeling is soft, and the fruit fragrance is pleasant. The sobering and refreshing effects can be realized after the eating. If people often eat the health care sobering jelly, the toxin in bodies can be eliminated, a certain effect is realized on the prevention and the treatment of intestinal cancer, constipation and cardiovascular diseases, and auxiliary curative effects are also realized on hyperlipidemia, diabetes and obesity. All ingredients of the health care sobering jelly provided by the invention are in plant types, the resources are convenient to obtain, the price is low, the preparation process is simple, no public hazard is caused on the environment, and the health care sobering jelly also has the advantages that the health care, sobering andrefreshing effects are realized, and the like.

The invention relates to a gene marker for detecting intestinal cancer and/or gastric cancer and application of the gene marker. The invention also relates to a method for detecting the intestinal cancer and/or the gastric cancer by using the gene marker.

The invention relates to the effective parts of rosemary, its preparation method and use, wherein the effective parts of the Rosmarinus officinalisl are diterpenoids phenols extracted from medicinal material of Rosmarinus officinalisl, the content of the phenols is over 45%, and the sum of the content of the carnosol and carnosic acid as the principal ingredients is over 13%. The preparing process comprises curing the Rosmarinus officinalisl medicinal material and cutting it into chunks, charging raffinate for extraction, cooling down the merged extract and filtrating, decolorizing with activated charcoal, concentrating the filtrate and charging in water, filtering, drying and disintegrating the filtering deposit. The effective parts of the Rosmarinus officinalisl can be used for preparing medicament for preventing and treating cardiovascular diseases, epigastric pain, uterocarcinoma, cervical carcinoma, intestinal cancer and breast cancer.

The invention provides an allogeneic antigen-presenting cell targeting KRAS mutation, a construction method and a preparation method of intestinal cancer specific CTL cell, which belong to the technical field of tumor targeting, the method for constructing the allogeneic antigen-presenting cell comprises the following steps: 1) analyzing the affinity of a combination of HLA typing and KRAS mutation sequence of a certain intestinal cancer patient, and selecting a combination of synthetic fusion genes with the highest affinity; 2) ligating the synthetic fusion gene to an expression vector to obtain a recombinant vector; and 3) transferring the recombinant vector to a healthy-derived monocyte, and performing induced culture to obtain the allogeneic antigen-presenting cell targeting KRAS mutation. The allogeneic antigen-presenting cell targeting KRAS mutation solve the problem that the allogeneic DC does not match the HLA typing of the patient, and can stimulate a stronger immune response.The colon cancer-specific CTL cell has the good killing effect on target cells.

The invention relates to a pharmaceutical composition containing artemisinin, artemisinin derivatives and a histon deacetylase (HDAC) inhibitor and an application thereof to prepare medicines for treating intestinal cancer, liver cancer, lung cancer, kidney cancer, gastric cancer, brain tumor, sarcoma, pancreatic cancer, ovarian cancer, breast cancer, prostate cancer or leukaemia. The pharmaceutical composition of the invention has obvious synergistic effect, thus improving curative effect of medicines, lowering administration dosage and reducing occurrence of side effect.

The invention relates to nutrition-intensified bread prepared by compounding, pre-fermenting, slicing, modeling, leavening and baking the following raw materials: flour, eggs, milk, white sugar, common salt, vegetable oil, yeast, water, spices and grease. The nutrition-intensified bread is characterized in that algae powder, bifidus factors, various vitamins and trace elements are added to the raw materials. The product of the invention contains more abundant and balanced nutrient substances, solves the problem of serious insufficient and unbalanced nutrient intake for domestic people through mutually compounding, acting, relying and coordinating various kinds of nutriment in the human bodies and has the efficacies of removing toxin, nourishing the face, preventing intestinal cancers and arteriosclerosis, lowering blood fat, blood sugar and blood pressure, eliminating lead and radioactive elements in the bodies, keeping alkaline body fluid, improving IQ (Intelligence Quotient) and prolonging the life span.

An application of the Japanese butterbur's extract (bakkenolide D, B, IVa and IIIa) in preparing the medicines for preventing and treating liver cancer, lung cancer, cervical cancer, intestinal cancer, kidney cancer, bread cancer, etc is disclosed.

The invention relates to an anti-tumor medicine, which is prepared by Chinese medicine raw materials. The composition and the weight ratio of the Chinese medicine raw materials are codonopsis pilosula 30-100 parts, fructus ligustri lucidi 20-40 parts, orange peel 20-40 parts, chrysanthemum 30-50 parts, paris polyphylla 10-20 parts, dandelion 20-30 parts, patrinia 15-25 parts, snakeskin 15-25 parts, schizonepeta 30-45 parts, red flowers 15-25 parts, potentilla discolor 3-11 parts and fructus forsythiae 0.2-0.8 part. The anti-tumor medicine has a comprehensive formula, brings out the best in each other, strengthens the body resistance, cultures the basis, repairs tissue cells and enables the cells to be regenerated, reverses disease cells to be normal, can effectively treat malignant tumor including long cancer, esophagus cancer, intestinal cancer, bladder cancer, breast cancer, ovarian cancer, lymph cancer, uterine cancer and the like. The Chinese medicine is convenient to manufacture and use, safe, has no side and toxic effect, and is an ideal anti-tumor medicine.

The present invention provides a culture medium and a culture method for colorectal cancer organoids. The culture medium comprises a basic culture medium Advanced DMEM/F12, specific additive factors and sterile water; wherein a mass ratio of the basic culture medium Advanced DMEM/F12 to the sterile water is 99:1; and the specific additive factors comprise B27 without vitamin A, N-acetylcysteine, EGF, Noggin, R-spondin 1, Wnt3a, CHIR99021, thiazovivin, Gastrin I, a penicillin-streptomycin mixture and Primocin. The culture medium is used to culture the colorectal cancer organoids, can maintain morphological structures and genetic characteristics of primary tissues, effectively reduces risks of microbial contamination in colorectal cancer culture, and improves success rate and survival rate of colorectal cancer organoid culture.

The invention relates to dibenzo iodonium salts represented by the following structural formula (I), and discloses a preparation method and an application thereof. In in-vitro experiments, the iodonium salts substantially inhibit the growths of cells of human-sourced pancreatic cancer, stomach cancer, colon cancer and other malignant tumors, and provide substantially killing effects against cells of ovarian cancer, lung cancer, liver cancer, leukemia, glioma, bone marrow cancer and other malignant tumors. In animal experiments, with the salts, the growths of human pancreatic cancer and colon cancer xenografts in nude mice can be substantially inhibited. The compounds can be used in developing novel antitumor medicines. (I) is shown below.